CR-9114 is under clinical development by Leyden Laboratories and currently in Phase I for Influenzavirus B Infections. According to GlobalData, Phase I drugs for Influenzavirus B Infections have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CR-9114’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CR-9114 overview
CR-9114 is under development for the protection against influenza A and influenza B virus. The drug candidate is a human monoclonal antibody having the broadest activity. It binds to the conserved epitope in the hemagglutinin (HA) stem and protects against the infection. It was also under development for the protection against influenza A (H1N1 and H3N2) and influenza B virus.
Leyden Laboratories overview
Leyden Laboratories (Leyden Labs) is a biotechnology research company. It’s targeting commonalities of viral families to protect humanity from known and future viruses that provides people with the freedom to protect themselves from infection and prevent transmission. Its portfolio includes accessible intranasal product candidates may provide people with the freedom to immediately protect themselves from and prevent the spread of many variants of respiratory viruses, including ones in the influenza and coronavirus. Leyden Labs is headquartered in Leiden, the Netherlands.
For a complete picture of CR-9114’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
